Jelly Roll Botox®: Technique, Dosing & Patient Selection

Last updated: September 2026

Jelly roll Botox® is one of the most requested and most misunderstood treatments in the lower face — and one of the easiest to get wrong. The target is a small band of muscle that sits a few millimetres below the lash line, so the difference between a subtly brighter eye and a patient who is unhappy with their smile can come down to two units and three millimetres. Getting it right starts with a working knowledge of the anatomy beneath each injection site.

Unlike the glabella or the crow’s feet, this area has no labeled dose to fall back on. What exists instead is a small, consistent body of published clinical work — including a dose-finding study that showed exactly where the risk curve turns upward. This guide pulls that evidence together: what the jelly roll actually is, where the needle goes, how many units is too many, which patients should be turned away, and what to do when a jelly roll appears because of a previous treatment.

Whether you are a clinic owner, an injector adding the lower lid to your repertoire, or a practitioner fielding the question from patients who saw it on social media, the goal is the same: know when the answer is yes, and be comfortable saying no.

Key Takeaways

What the “Jelly Roll” Actually Is

“Jelly roll” is the informal term for a small roll or bulge of muscle that appears under the eye, most visibly when a patient smiles or squints hard. It is not caused by fat or fluid the way under-eye bags, festoons and puffiness are. It is the contraction of the pretarsal portion of the orbicularis oculi — the sphincter muscle that encircles the eye — bunching up over the tarsal plate.

That distinction is the whole treatment decision, so it is worth being precise about it:

• Location. The jelly roll sits just beneath the lower eyelid margin, close to the lash line, and becomes more noticeable with smiling or forceful closure. It is higher on the lid than a true under-eye bag.
• Origin. Bags and festoons come from herniated fat pads, fluid or skin laxity and sit lower, over the orbital rim. The jelly roll is muscular and disappears at complete rest.
• Why patients ask. A prominent jelly roll can make a young, otherwise unlined under-eye look puffy or tired in photographs, which is why it is usually a patient in their twenties or thirties who raises it.

A simple test: ask the patient to relax completely, then to smile widely. If the roll only appears with the smile, it is muscular and is a candidate for toxin. If it is there at rest, you are looking at volume or laxity, and the wider question of what Botox® can and cannot do under the eyes applies instead.

Is Jelly Roll Botox® Off-Label?

Yes, and patients should hear it during consent. BOTOX® Cosmetic is FDA-approved for glabellar (frown) lines, lateral canthal lines (crow’s feet), forehead lines and platysma bands. The lower eyelid is not on that list. Injecting the pretarsal orbicularis to soften a jelly roll or widen the eye is an established off-label technique — supported by published clinical studies, but not by labeled dosing.

Practically, that means two things. There is no manufacturer-sanctioned unit range to hide behind, so your dose has to be defensible from the literature. And because there is no labeled indication, documentation of the discussion, the assessment and the dose matters more here than almost anywhere else on the face.

Where the Injection Goes

The technique described in the published work is narrow and specific. The injection is placed in the midpupillary line, approximately 3 mm below the ciliary (lash) margin, delivered just subdermally into the pretarsal orbicularis. Small volume, superficial plane, one point per side.

Three things keep that injection safe. Staying superficial keeps the toxin in the pretarsal muscle rather than letting it reach the lower lid retractors or the inferior oblique. Staying on the midpupillary point avoids drifting medially toward the lacrimal drainage or laterally into the zone already treated for crow’s feet. And keeping the volume small limits how far the toxin can spread from where you put it — in this area, diffusion is the complication.

How Many Units? What the Dose-Finding Data Shows

This is the part of the conversation that most often goes wrong, because the instinct — if a little works, more will work better — is exactly backwards here. Flynn and the Carruthers published two studies that map the dose-response curve in the lower lid, and the second one was designed specifically to ask whether going above 2 units is worth it.

It is not. Higher doses did produce slightly more eye-widening, but in the 8-unit groups every single patient reported bothersome side effects — lower eyelid swelling and incomplete sphincter function among them. The authors’ recommendation was to stay at 2 to 4 units. Think of the pretarsal muscle as the drawstring on a bag: loosen it a little and the gather smooths out, loosen it too far and the whole thing sags open.

Read the middle rows carefully, because they contain the useful clinical lesson: 2 units in the lid plus a standard crow’s feet treatment outperformed 8 units in the lid alone at rest. The synergy comes from treating the muscle as a unit rather than from loading one point — the same logic that drives how the lateral orbital area is dosed for crow’s feet. At the highest doses the benefit plateaus while the side effects keep climbing.

Botox® for Eye-Widening: What Is Realistic

Some patients want a rounder, more open-looking eye rather than a smoother lid. Relaxing the pretarsal muscle does widen the palpebral aperture — it has been measured — but the numbers are small, and managing that expectation is most of the consultation.

At 2 units in the lid alone, the average gain was half a millimetre at rest, and only 40% of patients showed any measurable increase at all. Adding the crow’s feet treatment raised that to 86% of patients and an average of 1.8 mm at rest. The published work also noted the effect was more notable in the Asian eye, where a rounder aperture is more often the aesthetic goal.

The demand side has changed since this technique first appeared. Eye-widening was once described as a mainly East Asian request; it is now a mainstream consumer search in North America and the UK, driven by social media. That does not make the millimetres bigger — it means more patients will arrive with expectations set by a filtered video, and the honest version of this number is your best tool.

Patient Selection: Who Should Not Be Treated

This is where the treatment is won or lost. The lower lid tolerates very little, and the margin for error narrows with age as the skin thins and the lid loses support. A tiny overdose in the wrong patient shows up as extra sclera (the white of the eye) or a smile that no longer looks like theirs.

Before treating, assess the lid rather than eyeballing the patient’s age:

• Snap-back test. Pull the lower lid down and away from the globe and release without letting the patient blink. A healthy lid snaps straight back. A lid that returns slowly, or only after a blink, has poor tone — do not add muscle weakness to it.
• Lid distraction test. Pinch the lid and pull it forward from the globe. Significant distraction indicates horizontal laxity and a higher risk of malposition.
• Fat pads at rest. If there is visible fat herniation with the face relaxed, the pretarsal muscle is acting as a corset over it. Relax the corset and the bag can look worse, not better.
• Prior lower blepharoplasty or existing scleral show. Both reduce the reserve you are borrowing against. Treat as a contraindication unless you know the surgical history well.
• Dry eye or watering history. The orbicularis drives the lacrimal pump. Weakening it can tip a marginal tear film into symptoms.

A structured assessment habit is what makes this consistent from patient to patient — the same discipline covered in our facial analysis checklist for Botox® trainees. When two or more of the findings above are present, the safe answer is to decline the lower lid and offer an alternative.

Complications and How to Avoid Them

Almost every problem in this area is dose-related, selection-related, or both. Knowing the specific failure modes is what lets you set expectations honestly and recognise a problem early:

• Lower eyelid swelling (malar or lid edema). The most common dose-related complaint, and the one that dominated the 8-unit groups in the dose-finding study. The orbicularis helps move lymph; weaken it and fluid lingers.
• Pseudo-eyelid bags. A 2025 prospective study of intradermal toxin for mild tear troughs in 42 patients reported one case — the muscle relaxes and the fat behind it becomes more visible. This is the answer to the patient who asks whether it can make things look worse.
• Excess scleral show. Too much white below the iris, giving a startled or hollow look. More likely in thin, older or lax lids.
• An odd or asymmetric smile. Uneven relaxation, or spread toward the mid-face muscles, produces a pinched or unbalanced smile — particularly noticeable when only some of the sphincter is relaxed.
• Watering or gritty eyes. A weakened lacrimal pump can cause both epiphora and dry-eye symptoms. Usually temporary, always unpleasant.
• Lower lid malposition or ectropion. Rare, and largely confined to patients who failed the laxity tests above.

Worth noting for consent: the lid complication patients ask about most is not the jelly roll itself but the eyelid dropping. That is a different mechanism entirely — see droopy eyelid after Botox® (ptosis) for how upper lid ptosis arises and how it is managed.

Why Some Patients Develop a Jelly Roll After Botox®

A question injectors field regularly: a patient who never had a jelly roll now has one, after a crow’s feet treatment. It is a balance problem, not a new condition. When the lateral orbicularis is relaxed and the pretarsal band below the lash line is left at full strength, the untreated portion can look and behave more prominently on smiling. Relative, not absolute, change.

The fix is usually small: a very low pretarsal dose at the next visit to even out the sphincter, or a change in crow’s feet placement at the following treatment. It is also a good argument for planning the periocular area as one unit from the start rather than treating each line in isolation.

How Long It Lasts

Onset is typically three to seven days, with periocular toxin effects generally lasting around three to four months. Because the doses here are so small, some patients notice the softening fading before their glabella or crow’s feet results do. Say that at consultation — a patient who was told to expect four months and sees movement return at ten weeks will read a normal result as a failure.

Toxin or Filler? Matching the Treatment to the Cause

Not all under-eye lines respond to toxin, and it is worth being blunt with patients about which of theirs will. Some lines are simply part of the eye’s natural structure rather than creases that can be erased. Others come from the lower orbicularis at rest, and a very small dose can soften those. But lines that appear mainly on smiling, or that originate in the cheek muscles, will not improve from a lower lid injection.

And when the underlying problem is lost volume or thinning skin as the face ages, toxin is the wrong tool entirely — volume replacement or a filler approach will serve the patient better, and offering it is often what earns their trust. The judgement call is the same one that runs through planning the full face as one balanced treatment: treat the cause you actually found, not the one the patient named.

Frequently Asked Questions

Is jelly roll Botox® FDA-approved?

No. BOTOX® Cosmetic is FDA-approved for glabellar (frown) lines, lateral canthal lines (crow’s feet), forehead lines and platysma bands. Injecting the pretarsal orbicularis oculi of the lower eyelid to soften a jelly roll or widen the eye is an off-label use. Off-label does not mean improper, but it does mean the technique rests on published clinical experience rather than on labeled dosing, and patients should be told that during consent.

How many units of Botox® are used for a jelly roll?

The published range is 2 to 4 units per lower eyelid. A dose-finding study by Flynn and colleagues compared 4 units with 8 units and found that every one of the eight patients in the 8-unit groups reported bothersome side effects, including lower eyelid swelling and incomplete eye closure. The authors recommended staying at 2 to 4 units. More toxin buys a fraction of a millimetre of extra eye opening and a much higher chance of an unhappy patient.

Where is jelly roll Botox® injected?

In the published technique the injection sits in the midpupillary line, approximately 3 millimetres below the ciliary (lash) margin, placed just subdermally into the pretarsal portion of the orbicularis oculi. It is a superficial, small-volume injection. Staying superficial and staying on that single midpupillary point is what keeps the toxin in the pretarsal muscle instead of diffusing toward the lower lid retractors or the inferior oblique.

Does jelly roll Botox® actually make the eyes look bigger?

Measurably, yes, but by very little. With 2 units in the lower lid alone, the palpebral aperture increased by an average of 0.5 mm at rest and 1.3 mm at full smile, and only 40 percent of patients showed any increase. When the lower lid was treated together with the crow’s feet, the average increase rose to 1.8 mm at rest and 2.9 mm at full smile, and 86 percent of patients showed an increase. The effect was described as more notable in the Asian eye. Patients expecting a dramatic change should be redirected.

Can jelly roll Botox® go wrong?

Yes. The recognised problems are lower eyelid swelling, excess scleral show, an asymmetric or pinched smile, watering or dry, gritty eyes from a weakened lacrimal pump, and — in a patient with true fat herniation — a bag that looks worse rather than better. A 2025 study of intradermal toxin for mild tear troughs reported one case of pseudo-eyelid bags among 42 patients. Almost all of these are dose- and selection-related, not bad luck.

Why did I get a jelly roll after Botox®?

It happens. When the lateral orbicularis is relaxed for crow’s feet and the pretarsal portion below the lash line is left at full strength, the untreated muscle can look and act more prominent on smiling, so a roll appears where there was none before. It is a balance problem rather than a new condition, and it is usually managed at the next visit with a very small pretarsal dose or by adjusting the crow’s feet placement.

How long does jelly roll Botox® last?

Onset is typically three to seven days, and periocular toxin effects generally last around three to four months. Because the doses used in the lower lid are so small, some patients notice the softening fading sooner than their frown line or crow’s feet results. That shorter tail is worth mentioning at consultation so a patient does not read a normal return of movement as a failed treatment.

The Bottom Line for Injectors

Jelly roll Botox® works, in the right patient, at the right dose, in the right plane. Two to four units, 3 mm below the lash margin, in the midpupillary line, in a patient whose lid snaps back and whose roll disappears at rest. Outside those conditions the treatment stops being subtle and starts being memorable for the wrong reasons — which is why the most valuable skill here is the confidence to decline and offer something better.

If you are adding the lower lid to your practice, the safest way to learn it is on live models with an instructor watching your plane and your volume. IAPAM’s hands-on Botox® training is taught by board-certified dermatologists in a clinical setting in Scottsdale, Arizona, and covers the periocular area as a planned unit rather than a set of isolated lines.

Explore Upcoming Botox® Training

Disclaimer: This guide is for informational and educational purposes only and does not constitute medical advice. Treatment plans, injection techniques, and dosing must be tailored to each patient by a qualified, licensed provider. Always follow product labeling, your scope of practice, and your state medical and nursing board regulations.